

## Correction to *Lancet Diabetes Endocrinol* 2025; 13: 119–33

Yang J, Burrello J, Goi J, et al. Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohort. *Lancet Diabetes Endocrinol* 2025; 13: 119–33—In this Article, the spelling of author Ying Song's name was incorrect. In this Article, Jun Yang and Renata Libianto have been added to the affiliation, Department of Endocrinology, Monash Health, Clayton, VIC, Australia. In the panel, the third bullet point under the Clinical outcomes subheading has been changed to a footnote, now cited in the second bullet point under the same subheading. The last sentence of the seventh paragraph of the results section has been corrected to read, "Of the participants with a complete clinical response, 160 (70%) were female, whereas of those with an absent clinical response, 88 (39%) were female." Appendix 14 of this Article has been corrected. These changes have been made to the online version as of Feb 3, 2025.

commission), and the rest of the table subsequently renumbered. Consequently, the final sentence of the Executive summary in the Commission should say "endorsed by more than 75 organisations worldwide". A Korean translation has been added to Appendix 1 and thus the list of translation languages for the Commission should be "Arabic, Chinese, French, German, Greek, Hindi, Italian, Japanese, Korean, Polish, Portuguese, Spanish, and Swedish". These corrections have been made to the online version as of Feb 25, 2025, and the printed version is correct.

Published Online  
February 3, 2025  
[https://doi.org/10.1016/S2213-8587\(25\)00021-X](https://doi.org/10.1016/S2213-8587(25)00021-X)

## Correction to *Lancet Diabetes Endocrinol* 2025; 13: 221–62

Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. *Lancet Diabetes Endocrinol* 2025; 13: 221–62—In this Commission, "Malaysian Association for the Study of Obesity (MASO) | Malaysia", "Obesity Canada | Canada", and "Sociedade Brasileira de Endocrinologia e Metabolismo (SBEM) | Brasil" should be present in Appendix 2 (Appendix 2.1 Table 1. Organisations that have endorsed the consensus statements of the